Co-author, Professor Kevin Schulman, MD of Stanford University, who is also a co-author on a drug quality scores paper, gives an overview in a Health Affairs Journal article of the generic medications market via the key example of cisplatin, the cancer drug that's badly on shortage after a key manufacturer had egregious quality problems: "The FDA documents are an indictment not just of Intas, but of a market that does not consider price and quality concurrently. In this case, poor product quality led to a disruption in a poor-quality supply chain. While cancer patients were knowingly harmed from drug shortages this year, the FDA documents suggest many more patients may have been unknowingly harmed from poor quality generic cancer drugs over the last 5 years. These quality issues are the result of a market that is a race to the bottom solely based on price."

Co-author, Professor Kevin Schulman, MD of Stanford University, who is also a co-author on a drug quality scores paper, gives an overview in a Health Affairs Journal article of the generic medications market via the key example of cisplatin, the cancer drug that's badly on shortage after a key manufacturer had egregious quality problems: "The FDA documents are an indictment not just of Intas, but of a market that does not consider price and quality concurrently. In this case, poor product quality led to a disruption in a poor-quality supply chain. While cancer patients were knowingly harmed from drug shortages this year, the FDA documents suggest many more patients may have been unknowingly harmed from poor quality generic cancer drugs over the last 5 years. These quality issues are the result of a market that is a race to the bottom solely based on price."